Previous 10 | Next 10 |
Yesterday, Novocure's stock price made a huge jump of 50% because of an update of its LUNAR study. We look at the history of the company and the key people. Novocure already has 3 FDA approvals, 2 for glioblastoma and 1 for mesothelioma, but its total addressable market is much bi...
Yesterday, NovoCure ([[NVCR]] -5.2%) and its partner Zai Lab ([[ZLAB]] +2.7%) announced that a data monitoring committee (“DMC”) has recommended a reduced duration and sample size for its Phase 3 trial for Tumor Trial Fields (“TTF”) treatment in non-small cell...
Ongoing profitability a question mark at OrganigramCIBC analyst John Zamparo doesn't see Organigram Holdings (OGI) returning to positive EBIDTA soon, leading him to cut shares to underperformer and reducing his price target to C$3.25 from C$5.He says the COVID-19 pandemic will continue to imp...
Shares of Novocure (NASDAQ: NVCR) soared nearly 50% on Tuesday after the oncology company provided an update on a phase 3 trial of its experimental lung cancer treatment. An independent data monitoring committee (DMC) informed Novocure that an interim analysis for the study ...
Shares of NovoCure Limited (NASDAQ:NVCR) traded today at $218.12, eclipsing its 52-week high. Approximately 1.1 million shares have changed hands today, as compared to an average 30-day volume of 753,000 shares. NovoCure Ltd serves in the healthcare sector of the United States. Its busin...
Gainers: Mackinac Financial (MFNC) +56%.NovoCure (NVCR) +42%.vTv Therapeutics (VTVT) +42%.Digimarc (DMRC) +20%.PLBY Group (PLBY) +20%.Ballantyne Strong (BTN) +20%.Birks Group (BGI) +18%.Zai Lab (ZLAB) +16%.B. Riley Financial (RILY) +15%.Nam Tai Property (NTP) +14%.Losers: Brook...
After reviewing interim results from 210 patients participating in a phase 3 study, an independent monitoring committee is recommending changes to Novocure 's (NASDAQ: NVCR) non-small cell lung cancer (NSCLC) trial. Specifically, the committee is suggesting that the number of patien...
Gainers: NovoCure (NVCR) +45%, vTv Therapeutics (VTVT) +28%, Rigel Pharmaceuticals (RIGL) +15%, Zai Lab (ZLAB) +14%, Vallon Pharmaceuticals (VLON) +10%.Losers: Avenue Therapeutics (ATXI) -17%, AdaptHealth (AHCO) -17%, Brook...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of oncology firm Novocure (NASDAQ: NVCR ) stock are soaring to start the day on Tuesday following a promising update from its phase 3 tumor-treating trial . Source: CI Photos / Shutterstock.com An inde...
NovoCure Limited (NVCR) +62% after DMC recommends shorter phase 3 NSCLC trial.Mackinac Financial Corporation (MFNC) +31% on merger agreement with Nicolet Bankshares.Dragon Victory International Limited (LYL) +44%.Optibase (OBAS) +20%.Tian Ruixiang Holdings Ltd (TIRX) +26%.vTv Therap...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...